Table 1. Clinical data and PASI score on the study patients.
| Gender | PASIWk 0 | PASIWk 12 | % Wk 12 to W0a | PASI @recurrence | % loss of improvement | Relapseb | % change at recurrence | Reboundc |
| Fd | 60 | 2.7 | −96% | 46.2 | 76% | Y | 77% | N |
| Md | 12.2 | 3.4 | −72% | 16.6 | 150% | Y | 136% | Y |
| Fd | 30.8 | 9.2 | −70% | 35.8 | 123% | Y | 116% | N |
| Fd | 35.2 | 8.9 | −75% | 42.9 | 129% | Y | 122% | N |
| M | 24 | 3.8 | −84% | 16.5 | 63% | Y | 69% | N |
| M | 35.2 | 11.4 | −68% | 36.8 | 107% | Y | 105% | N |
| M | 49.8 | 8.9 | −82% | 31.8 | 56% | Y | 64% | N |
| M | 46.2 | 34.8 | −25% | 41.2 | 56% | Y | 89% | N |
a
% change week 12 compared to week 0
b
all patients experienced a relapse between weeks 14–22, defined as loss of 50% of PASI improvement from baseline [5], [6].
c
only 1 patient experienced a rebound, said to occur if the PASI is 125% or greater than baseline, or if new generalized pustular, erythrodermic or more inflammatory psoriasis occurs within 3 months of stopping therapy [5], [6].
d
Genomic characterization on first 4 patients in this table.